Racecadotril
Racecadotril is not recommended for routine use in acute diarrhea based on current high-quality evidence, despite being mentioned as an option in some international guidelines.
Evidence Assessment
The 2017 IDSA guidelines, which represent the most authoritative and recent guidance for infectious diarrhea management, do not recommend racecadotril 1. These guidelines note that racecadotril reduces stool volume but is not available in North America 2. The guidelines emphasize that oral rehydration solution (ORS) remains first-line therapy, with antimotility agents like loperamide considered only as ancillary treatment once adequate hydration is achieved 1.
A critical 2019 Cochrane systematic review found insufficient evidence to support routine use of racecadotril 3. This high-quality meta-analysis of 7 RCTs (1,140 children) concluded that while racecadotril appears safe, it provides little benefit in improving acute diarrhea outcomes. Most importantly, a 2026 systematic review using rigorous methodology (REB method) found only one low-risk-of-bias trial, which showed neither statistically nor clinically significant effects 4. The conclusion was "absence of evidence" for efficacy.
Mechanism and Pharmacology
Racecadotril is an enkephalinase inhibitor that works by preventing degradation of endogenous enkephalins, thereby reducing intestinal water and electrolyte hypersecretion without affecting gut motility 5, 6. Unlike loperamide, it does not slow intestinal transit, theoretically reducing constipation risk.
Dosing (Where Available)
For children (3 months to 5 years):
- 1.5 mg/kg orally every 8 hours 7, 8
- Given as adjunct to oral rehydration therapy
- Duration typically 3-5 days
For adults:
Contraindications and Precautions
- Contraindicated in bloody diarrhea or febrile diarrhea (suggests invasive pathogens requiring different management) 1
- Not for use in inflammatory diarrhea
- Avoid in suspected toxic megacolon
- Not recommended in children under 3 months
Adverse Effects
Racecadotril demonstrates a favorable safety profile comparable to placebo 10, 3:
- Most adverse events are mild and transient 7
- Significantly less rebound constipation than loperamide 9, 11
- Less abdominal discomfort compared to loperamide 9
- No serious adverse events reported in major trials 6
Clinical Context
The fundamental issue is that racecadotril addresses symptoms rather than outcomes that matter most—morbidity and mortality. The 2017 IDSA guidelines make clear that ORS is the cornerstone of treatment (strong recommendation, moderate evidence) 1. Any ancillary agent, including racecadotril, is not a substitute for proper fluid and electrolyte therapy 1.
When Racecadotril Might Be Considered (in regions where available):
- Non-bloody, non-febrile acute watery diarrhea in adequately hydrated patients
- As adjunct to—never replacement for—ORS
- When loperamide is contraindicated (children <18 years) 1
- In settings where reducing stool output may improve quality of life during illness
Critical Pitfalls to Avoid:
- Never use racecadotril as monotherapy—ORS remains essential
- Do not use in febrile or bloody diarrhea—these require evaluation for invasive pathogens
- Do not delay appropriate antimicrobial therapy when indicated (dysentery, severe illness, immunocompromised patients) 1
- Avoid in children with signs of dehydration—rehydrate first 1
Practical Recommendation
In North America, racecadotril is not available and not necessary. Follow IDSA guidelines: prioritize ORS for rehydration, consider loperamide in adults only after adequate hydration (avoiding use in children <18 years or in bloody/febrile diarrhea), and reserve antimicrobials for specific indications 1, 2.
In regions where racecadotril is available, the evidence does not support its routine use over standard care with ORS alone 3, 4. If used, it should only be as adjunctive therapy in carefully selected patients with non-complicated acute watery diarrhea, recognizing that clinical benefit remains uncertain despite a good safety profile.